Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen mVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Worldwide product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, FY2025
771
Period ended Dec 31, 2025
Change on a year earlier
+6.1%
727 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 771 | +6.1% | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 727 | -9.1% | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 800 | -11.2% | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 901 | -22.7% | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 1,166 | +46.1% | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 798 | +528.3% | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 127 | – | Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗ |
Breakdown
What makes up mvasi (bevacizumab-awwb — avastin oncology biosimilar) — worldwide product sales ($m)
- MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — U.S. product sales ($M)573 · FY2025
- MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Rest of World (ROW) product sales ($M)198 · FY2025
- MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Worldwide reported sales growth YoY (%)6.0% · FY2025
Cite this data
StockData. (2026). Amgen MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Worldwide product sales ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_mvasi_ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.